

**SEER Site-Specific Coding Guidelines****LYMPH NODES****Lymph Nodes C770–C779**

*Note: Surgery codes for lymph nodes (C770-C779) are not limited to lymphomas.*

**Primary Site - Nodal vs. Extra-nodal**

1. When multiple lymph node chains are involved at the time of diagnosis, do not simply code the lymph node chain that was biopsied.
  - a. If it is possible to determine where the disease originated, code the primary site to that lymph node chain.
  - b. If multiple lymph node chains are involved and it is not possible to determine the lymph node chain where the disease originated, code the primary site to C778, lymph nodes of multiple regions.
2. If a lymphoma is extranodal, code the organ of origin.

**Example:** Pathology from stomach resection shows lymphoma. No other pathologic or clinical disease identified. Code the primary site as stomach, NOS (C169).

3. If a lymphoma is present both in an extranodal site and in that organ's regional lymph nodes, code the extralymphatic organ as the primary site. The only exception would be if the lymphoma in the extranodal site were a direct extension from the regional nodes. Lymphomas can spread from the regional lymph nodes into an extranodal site only by direct extension.

**Example 1:** Lymphoma is present in the spleen and splenic lymph nodes. Code the primary site to spleen (C422).

**Example 2:** Lymphoma is present in the stomach and the gastric lymph nodes. Code the primary site to stomach, NOS (C169).

4. If the lymphoma is present in extralymphatic organ(s) and non-regional lymph nodes, consult the physician to determine a primary site. If a site cannot be determined, code Lymph Node, NOS (C779).
5. Code the diagnosis of chronic lymphocytic leukemia (9823/3) and/or small lymphocytic lymphoma (9670/3) to SLL if there are positive lymph nodes or deposits of lymphoma/leukemia in organs or in other tissue. Code the histology to CLL if there are no physical manifestations of the disease other than a positive blood study or positive bone marrow, and code the primary site to bone marrow (C421).
6. If the primary site is unknown or not given:
  - a. Code retroperitoneal lymph nodes if described as retroperitoneal mass
  - b. Code inguinal lymph nodes if described as inguinal mass
  - c. Code mediastinal lymph nodes if described as mediastinal mass
  - d. Code mesenteric lymph nodes if described as mesenteric mass
  - e. If the primary site is unknown code Lymph Nodes, NOS (C779)

**Exception:** Code unknown primary site (C809) only when there is no evidence of lymphoma in lymph nodes and/or the medical record documents that the physician suspects that it is an extranodal lymphoma

Code **mycosis fungoides** and **cutaneous lymphomas** to Skin (C44\_).

### **Grade**

DO NOT code the descriptions “high grade,” “low grade,” or “intermediate grade” in the Grade, Differentiation or Cell Indicator field. FOR LYMPHOMA ONLY, the terms “high grade,” “low grade,” and “intermediate grade” refer to the Working Formulation of lymphoma diagnoses. The Working Formulation is not a grade or differentiation.

DO NOT code the descriptions “Grade 1,” “Grade 2,” or “Grade 3” in the Grade, Differentiation or Cell Indicator field. FOR LYMPHOMA ONLY, the terms “Grade 1,” “Grade 2,” and “Grade 3” represent lymphoma types, rather than differentiation.

The designation of **T-cell**, **B-cell**, **null cell**, or **NK cell** has precedence over any statement of grading or differentiation. Code ANY statement of T-cell, B-cell, null cell, or NK cell. Code information on cell type from any source, whether or not marker studies are documented in the patient record

**Example:** The history portion of the medical record documents that the patient has a T-cell lymphoma. There are no marker studies in the chart. Code the grade as T-cell.

### **Additional Terms to be Coded**

#### **T-cell (code 5)**

T-cell phenotype  
T-precursor  
Pre-T  
Gamma-Delta T

#### **B-Cell (code 6)**

B-cell phenotype  
B-precursor  
Pre-B

#### **Null-Cell; Non-T-non-B (code 7)**

Null-cell  
Non T-non-B  
Common cell

#### **NK (natural killer) cell (code 8)**

Nasal NK/T cell lymphoma  
Combined T and B cell

**Cell type not determined, not stated, not applicable (code 9)**

Combined T and B cell

**Regional Lymph Nodes Positive and Regional Lymph Nodes Examined**

These two fields are always coded '99' for both nodal and extranodal lymphomas

Refer to Appendix E to determine multiple primaries for Hematopoietic disease.

If the physician clearly states that a hematopoietic diagnosis is a new primary, use that information. Otherwise, use the SEER table "Definitions of Single and Subsequent Primaries for Hematologic Malignancies found in Appendix E.

*Note: For all Lymphomas, Collaborative Stage must be coded using the schema for the histologic type group.*

**Collaborative Staging Codes****Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)****(ICD-O-3 M-959-972 EXCEPT 9700/3 and 9701/3****(ICD-0-3 M-9823, 9827, EXCEPT C42.0, C42.1, C42.4)****Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)****CS Tumor Size (Revised: 08/02/2004)**

Code	Description
888	Not applicable

**Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)****CS Extension (Revised: 08/01/2007)**

**Note 1:** For lymphoma an E lesion is defined as disease that involves extralymphatic site(s). Extralymphatic means other than lymph nodes and other lymphatic structures. These lymphatic structures include spleen, thymus gland, Waldeyer's ring (tonsils), Peyer's patches (ileum) and lymphoid nodules in the appendix. Any lymphatic structure is to be coded the same as a lymph node region.

**Note 2:** S equals Spleen involvement.

**Note 3:** If there is no mention of extranodal involvement but several diagnostic procedures were done, including laparotomy, interpret as no involvement.

**Note 4:** Involvement of adjacent soft tissue does not alter the classification.

Code	Description	TNM	SS77	SS2000
10	Involvement of a single lymph node region Stage I	*	L	L
11	Localized involvement of a single extralymphatic organ/ site in the absence of any lymph node involvement Multifocal involvement of one extralymphatic organ/site Stage IE	*	L	L
12	Involvement of spleen only Stage IS	*	L	L
20	Involvement of two or more lymph node regions on the SAME side of the diaphragm Stage II	*	RNOS	RNOS
21	Localized involvement of a single extralymphatic organ/site WITH involvement of its regional lymph node(s) or WITH or WITHOUT involvement of other lymph node(s)	*	RNOS	RNOS

21 cont'd	on the SAME side of the diaphragm Direct extension to adjacent organs or tissues Stage IIE	*	RNOS	RNOS
22	Involvement of spleen PLUS lymph node(s) BELOW the diaphragm Stage IIS	*	RNOS	RNOS
23	Involvement of spleen PLUS involvement of a single extralymphatic organ/site BELOW the diaphragm WITH/WITHOUT involvement of lymph node(s) BELOW the diaphragm Stage IIES	*	RNOS	RNOS
30	Involvement of lymph node regions on BOTH sides of the diaphragm Stage III	*	D	D
31	Involvement of an extralymphatic organ/site PLUS involvement of lymph node(s) on the OPPOSITE side of the diaphragm Stage IIIE	*	D	D
32	Involvement of the spleen PLUS lymph node(s) ABOVE the diaphragm Involvement of the spleen PLUS lymph node(s) on both sides of the diaphragm Stage IIIS	*	D	D
33	(31) + (32) OR Involvement of the spleen PLUS a single extralymphatic site ABOVE the diaphragm WITH/WITHOUT involvement of lymph node(s) Involvement of the spleen PLUS involvement of lymph node region(s) ABOVE the diaphragm PLUS involvement of a single extralymphatic organ/site on either side of the diaphragm Stage IIIES	*	D	D
80	Diffuse or disseminated (multifocal) involvement of ONE OR MORE extralymphatic organ(s)/site(s) WITH or WITHOUT associated lymph node involvement Multifocal involvement of MORE THAN ONE extralymphatic organ/site Involvement of isolated extralymphatic organ in absence of involvement of adjacent lymph nodes, but in conjunction with disease in distant sites	*	D	D

80 cont'd	Metastasis/involvement: Bone marrow Liver Nodular involvement of lung(s) Stage IV	*	D	D
99	Unknown extension Primary tumor cannot be assessed Not documented in patient record	*	U	U

### Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

#### CS TS/Ext-Eval (Revised: 08/21/2006)

**Note:** According to AJCC, "The use of the term pathologic staging is reserved for patients who undergo staging laparotomy with an explicit intent to assess the presence of abdominal disease or to define histologic microscopic disease extent in the abdomen. Staging laparotomy and pathological staging have been essentially abandoned as useful procedures." (6th ed., page 396) Therefore, Collaborative Staging uses a modified evaluation scheme for lymphomas, and it applies to the CS TS/EXT-EVAL field only. The other EVAL fields are coded as "not applicable" for this schema

Code	Description	Staging Basis
0	No Staging laparotomy done. No autopsy evidence used	c
3	Staging laparotomy done	p
8	Evidence from autopsy only (tumor was unsuspected or undiagnosed prior to autopsy).	a
9	Unknown if staging laparotomy done Not assessed; cannot be assessed Unknown if assessed Not documented in patient record	c

### Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

#### CS Lymph Nodes (Revised: 05/07/2004)

Code	Description	TNM	SS77	SS2000
88	Not applicable	NA	U	U

### Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

#### Reg LN Pos (Revised: 05/17/2006)

Code	Description
99	Not applicable for this site

**Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)****Reg LN Exam (Revised: 05/17/2006)**

Code	Description
99	Not applicable

**Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)****CS Mets at DX (Revised: 05/07/2004)**

Code	Description	TNM	SS77	SS2000
88	Not applicable for this site	NA	U	U

\*Lymph node chains are subsites of lymph node regions. Use information pertaining to lymph node chains to code lymph node surgery; use lymph node region information to code stage.

**Collaborative Staging Codes****Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms**

(M-9731-9734, 9740-9742, 9750-9758, 9760-9762, 9764-9769, 9800-9801, 9805, 9820, 9823 [C420, C421, or C424 ONLY], 9826, 9827[C420, C421, or C424 ONLY], 9831-9837, 9840, 9860-9861, 9863, 9866-9867, 9870-9876, 9891, 9895-9897, 9910, 9920, 9930-9931, 9940, 9945-9946, 9948, 9950, 9960-9964, 9970, 9975, 9980, 9982-9987, 9989)

**Note:** This list includes only preferred terms from ICD-O-3

9731 Plasmacytoma, NOS	9866 Acute promyelocytic leukemia
9732 Multiple myeloma	9867 Acute myelomonocytic leukemia
9733 Plasma cell leukemia	9870 Acute basophilic leukemia
9734 Plasmacytoma, extramedullary	9871 Acute myeloid leukemia with abnormal marrow, eosinophils
9740 Mast cell sarcoma	9872 Acute myeloid leukemia, minimal differentiation
9741 Malignant mastocytosis	9873 Acute myeloid leukemia without maturation
9742 Mast cell leukemia	9874 Acute myeloid leukemia with maturation
9750 Malignant histiocytosis	9875 Chronic myelogenous leukemia, BCR/ABL positive
9751 Langerhans cell histiocytosis, NOS*	9876 Atypical chronic myeloid leukemia BCR/ABL negative
9752 Langerhans cell histiocytosis, unifocal*	9891 Acute monocytic leukemia
9753 Langerhans cell histiocytosis, multifocal*	9895 Acute myeloid leukemia with multilineage dysplasia
9754 Langerhans cell histiocytosis disseminated	9896 Acute myeloid leukemia, t(8;21)(q22;q22)
9755 Histiocytic sarcoma	9897 Acute myeloid leukemia, 11q23 abnormalities
9756 Langerhans cell sarcoma	9910 Acute megakaryoblastic leukemia
9757 Interdigitating dendritic cell sarcoma	9920 Therapy-related acute myeloid leukemia, NOS
9758 Follicular dendritic cell sarcoma	9930 Myeloid sarcoma
9760 Immunoproliferative disease, NOS	9931 Acute panmyelosis with myelofibrosis
9761 Waldenstrom macroglobulinemia	9940 Hairy cell leukemia
9762 Heavy chain disease, NOS	9945 Chronic myelomonocytic leukemia, NOS
9764 Immunoproliferative small intestinal disease	9946 Juvenile myelomonocytic leukemia
9765 Monoclonal gammopathy of undetermined significance*	9948 Aggressive NK-cell leukemia
9766 Angiocentric immunoproliferative lesion*	9950 Polycythemia (rubra) vera
9767 Angioimmunoblastic lymphadenopathy*	9960 Chronic myeloproliferative disease, NOS
9768 T-gamma lymphoproliferative disease*	
9769 Immunoglobulin deposition disease*	
9800 Leukemia, NOS	
9801 Acute leukemia, NOS	
9805 Acute biphenotypic leukemia	
9820 Lymphoid leukemia, NOS	
9823 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma[C420, C421, or C424 ONLY]	
9826 Burkitt cell leukemia	

<p>9827 Adult T-cell leukemia/lymphoma (HTLV-1 positive) [C420, C421, or C424 ONLY]</p> <p>9831 T-cell large granular lymphocytic leukemia*</p> <p>9832 Prolymphocytic leukemia, NOS</p> <p>9833 Prolymphocytic leukemia, B-cell type</p> <p>9834 Prolymphocytic leukemia, T-cell type</p> <p>9835 Precursor cell lymphoblastic leukemia, NOS</p> <p>9836 Precursor B-cell lymphoblastic leukemia</p> <p>9837 Precursor T-cell lymphoblastic leukemia</p> <p>9840 Acute myeloid leukemia, M6 type</p> <p>9860 Myeloid leukemia, NOS</p> <p>9861 Acute myeloid leukemia, NOS</p> <p>9863 Chronic myeloid leukemia</p> <p>*Usually considered of uncertain/borderline behavior</p> <p>9964 Hypereosinophilic syndrome</p>	<p>9961 Myelosclerosis with myeloid metaplasia</p> <p>9962 Essential thrombocythemia</p> <p>9963 Chronic neutrophilic leukemia</p> <p>9970 Lymphoproliferative disorder, NOS*</p> <p>9975 Myeloproliferative disease, NOS*</p> <p>9980 Refractory anemia, NOS</p> <p>9982 Refractory anemia with sideroblasts</p> <p>9983 Refractory anemia with excess blasts</p> <p>9984 Refractory anemia with excess blasts in transformation</p> <p>9985 Refractory cytopenia with multilineage dysplasia</p> <p>9986 Myelodysplastic syndrome with 5q deletion (5q-) syndrome</p> <p>9987 Therapy-related myelodysplastic syndrome, NOS</p> <p>9989 Myelodysplastic syndrome, NOS</p>
---	---

**Collaborative Staging Codes**

**Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms**

Note: AJCC does not define TNM staging for this site.

**Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms**

**CS Tumor Size (Revised: 01/16/2003)**

Code	Description
888	Not applicable

**Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms**

**CS Extension (Revised: 08/15/2006)**

Code	Description	TNM	SS77	SS2000
10	Localized disease: (single/solitary/unifocal/isolated/monostotic) may be coded for: Plasmacytoma, NOS (M-9731/3) (solitary myeloma) Plasmacytoma, extramedullary (M-9734/3) (not occurring in bone) Mast cell sarcoma (M-9740) Malignant histiocytosis (M-9750) Histiocytic sarcoma (M-9755)	NA	L	L

10 cont'd	Langerhans cell sarcoma (M-9756) Dendritic cell sarcoma (M-9757, M-9758) Myeloid sarcoma (M-9930)	NA	L	L
80	Systemic disease (poly-ostotic): All histologies including those in 10	NA	D	D
99	Unknown	NA	D	D

**Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms**

**CS TS/Ext-Eval (Revised: 03/17/2004)**

Code	Description	Staging Basis
9	Not applicable for this site	NA

**Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms**

**CS Lymph Nodes (Revised: 05/07/2004)**

Code	Description	TNM	SS77	SS2000
88	Not applicable	NA	U	U

**Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms**

**Reg LN Pos (Revised: 05/17/2006)**

Code	Description	TNM	SS77	SS2000
99	Not applicable	NA	U	U

**Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms**

**Reg LN Exam (Revised: 05/17/2006)**

Code	Description	TNM	SS77	SS2000
99	Not applicable	NA	U	U

**Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms**

**CS Mets at DX (Revised: 05/07/2004)**

Code	Description	TNM	SS77	SS2000
88	Not applicable	NA	U	U

**Site-Specific Surgery Codes****Lymph Nodes****C770-C779**

(Except for M-9750, 9760-9764, 9800-9820, 9826, 9831-9920, 9931-9964, 9980-9989)

**Note: For Surgery Codes only: see site-specific scheme for primary sites other than C770-C779**

**Codes**

- 00 None; **no surgery** of primary site; **autopsy ONLY**
- 19 Local tumor destruction or excision, NOS  
**Unknown whether a specimen was sent to pathology for surgical events coded to 19 (principally for cases diagnosed prior to January 1, 2003)**
- 15 Local tumor destruction, NOS  
No specimen sent to **pathology** from surgical event 15
- 25 **Local tumor excision**, NOS  
Less than a full chain; includes a **lymph node biopsy**
- 30 Lymph node dissection, NOS
  - 31 One chain
  - 32 Two or more chains
- 40 Lymph node dissection, NOS PLUS splenectomy
  - 41 One chain
  - 42 Two or more chains
- 50 Lymph node dissection, NOS and partial/total removal of adjacent organ(s)
  - 51 One chain
  - 52 Two or more chains
- 60 **Lymph node dissection**, NOS and partial/total removal of **adjacent organ(s)** PLUS **splenectomy** (Includes staging laparotomy for lymphoma)
  - 61 One chain
  - 62 Two or more chains
- 90 Surgery, NOS
- 99 **Unknown** if surgery performed; **death certificate ONLY**

[**SEER Note:** Lymph node chains are subsites of lymph node regions. Use information pertaining to lymph node **chains** to code lymph node surgery; use lymph node **region** information to code stage.]

**Site-Specific Surgery Codes**  
**Hematopoietic/Reticuloendothelial/  
Immunoproliferative/Myeloproliferative Disease**  
**C420, C421, C423, C424 (with any histology)**

or

**M-9750, 9760–9764, 9800–9820, 9826, 9831–9920, 9931–9964,  
9980–9989 (with any site)**

Codes

98 **All hematopoietic/reticuloendothelial/immunoproliferative/myeloproliferative disease sites and/or histologies, WITH or WITHOUT surgical treatment**

*Surgical procedures for hematopoietic, reticuloendothelial, immunoproliferative, myeloproliferative primaries are to be recorded using the data item Surgical Procedure/Other Site (NAACCR Item # 1294)*